Lōkahi Therapeutics™ Announces Qare™, the First Real-Time Comparative Health Platform for GLP-1 Medications, with Public Availability Beginning October 14
Lōkahi Therapeutics, the subsidiary of Glucotrack (NASDAQ: GCTK), announced Qare, a comparative health platform for GLP-1 medications that lets users compare treatment experiences against similar patient cohorts. Qare becomes publicly available on October 14, 2026, launching in the GLP-1 category with additional drug classes expected to follow. CEO Erik Emerson framed the launch against a roughly $70 billion healthcare analytics market, arguing patients who generate the data do not benefit from it today.
Key figures
- Public availability date
- October 14, 2026
- Healthcare analytics market size
- $70 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.